In recent years, induction chemotherapy has been tested by several investigators in the management of operable breast cancer.
Patients and methods
Our current study was aimed to evaluate, pragmatically, in patients (74 stage II and 30 stage III) whose treatment would have been mastectomy, the percentage of them in whom a conservative treatment can be performed if primarily treated with a mitoxantrone/vinorelbine regimen.
67/104 patients (64%; 95% CI: 55–74%) had a conservative treatment (lumpectomy: 54, radiation therapy: 12, radiation therapy then lumpectomy: 1). Neutropenia was the major dose-limiting side effect, with grade 3 or 4 neutropenia registered in 83% of patients and 53.3% of the 442 cycles. Overall, a grade 3 or 4 non hematologic side effect occurred in 19.8% of patients and in 9.1% of cycles. One toxic death was observed after 2 cycles in a patient with aplasia who developped septicemia. Seventy one per cent of the patients experienced nausea and vomiting but grade 3 were observed in only 12% of the patients. Other side effects, including stomatitis, asthenia, alopecia, and constipation, were generally mild and uncommon.
This mitoxantrone/vinorelbine regimen is an efficient induction treatment with only neutropenia as a noticeable side effect. It allows 64% of conservative treatment in patients whose treatment would have been mastectomy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, Mac Neese RN, Paulus D, Holmes FA, Romsdahl MM, Fraschini G, Mac Bride CM, Martin RG, Montague E: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–2516, 1988
Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, Housset M, Forget G, Thill L, Soubrane C, Khayat D: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–129, 1990
Bélembaogo E, Feillel V, Chollet P, Curé H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J, Bignon YJ, de Latour M, Lafaye C, Dauplat J: Neoadjuvant chemotherapy in 126 operable breast cancer. Eur J Cancer 28A: 896–900, 1992
Bonnadonna G: From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steimer Award lecture 1992. Int J Cancer 55: 1–4, 1993
Mauriac L, Durand M, Avril A, Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347–354, 1991
Smith IE, Jones AI, O'Brien MER, Mc Kinna JA, Sacks N, Baum M. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 592–595, 1993
Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, Bougnoux P, Lansac J, Le Floch O: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74: 1283–1288, 1994
Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, Garcio-Giralt E, Salmon RJ, de la Rochefordière A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6, Eur J Cancer 30A: 645–652, 1994
Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, Mc Kinna JA, Baum M: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424–429, 1995
Goldie JH, Coldman A: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733, 1979
Kurtz JM: Should surgery remain the initial treatment of operable breast cancer? Eur J Cancer 27: 1539–1542, 1991
Chabner BA, Myers CE: Antitumor Antibiotics. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 374–384
Coleman RE, Maisey MN, Knight RK, Rubens RD: Mitoxantrone in advanced breast cancer: a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 6: 771–776, 1984
Harris AL, Cantwell BMJ, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RGB: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: 186–190, 1990
Wilson KS, Paterson AHG: First-line mitoxantrone chemotherapy for advanced brast cancer. Cancer Treat Rep 70: 1021–1022, 1986
Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A, Smyth J: Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Invest New Drugs 3: 139–148, 1985
Cowan JD, Neidhart JA, McClure S, Coltman CA, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst 83: 1077–1084, 1991
Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672–677, 1986
Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571, 1989
Pouillart P, Follézou JY, Palangie T, Feuilhade F, George C, Richard E: Long-term results of a randomized trial comparing regimens of cyclophosphamide and fluorouracil with either mitoxantrone or doxorubicin in patients with advanced breast cancer. Eur J Cancer 30A: 715–716, 1994
Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A, Schoch I: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and 5-fluorouracil and doxorubicin, cyclophosphamide and 5-fluorouracil in the therapy of metastatic breast cancer. J Clin Oncol 6: 1611–1620, 1988
Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P: Phase II trial of weekly intravenous vinorelbine in firstline advanced breast cancer chemotherapy. J Clin Oncol 11: 1245–1252, 1993
Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423–426, 1994
Spielmann M, Brain E, Sari C: Salvage chemotherapy (CT) with combination of mitoxantrone (MTZ) and vinorelbine (VNR) in resistant to anthracyclines advanced breast cancer (ABC). Fourth International Congress on Neoadjuvant Chemotherapy, Paris, France, February 2–5, 1993 (abstr 14)
Ferrero JM, Pivot X, Namer M, Wendling JL, Frenay M, Francois E, Hoch M, Teissier E: Mitoxantrone-vinorelbine as first line chemotherapy in metastatic breast cancer. Bull Cancer 82: 202–207, 1995
Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, MayLevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle S: Phase II trial of vinorelbine-doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764–1770, 1994
Miller AB, Hoogstraten B, Staquet M, Winkeler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981
Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, Mac Vicar D, Fernando I, Ford HT: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–552, 1995
Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P: Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8; 16): a report on 25 cases and review of the literature. J Clin Oncol 11: 2370–2379, 1993
Ragaz J, Aird R, Goldie J, Coldman A, Lee N, Worth A: (Preoperative neoadjuvant) therapy for breast cancer. Early results of the northamerican studies. International Symposium on Neoadjuvant treatment of Surgical Breast carcinoma. Madrid, 3/25/1994 (abstract)
Fisher B: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537–540, 1995
About this article
Cite this article
Adenis, A., Vanlemmens, L., Fournier, C. et al. Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer?. Breast Cancer Res Tr 40, 161–169 (1996). https://doi.org/10.1007/BF01806211